{"result": "(\"entity\"<|>PKU<|>EVENT<|>Phenylketonuria (PKU) is a metabolic disorder that requires dietary management to prevent neurological issues.)\n##\n(\"entity\"<|>SA-PROPTERINA<|>ORGANIZATION<|>Sapropterin is a commercial preparation used in the treatment of PKU, containing 100 mg tablets for oral administration.)\n##\n(\"entity\"<|>GLUCOMACROPEPTIDE<|>ORGANIZATION<|>Glucomacropeptide (GMP) is a large peptide derived from dairy that is low in phenylalanine and used in dietary management for PKU.)\n##\n(\"entity\"<|>BCAA<|>EVENT<|>Branched-chain amino acids (BCAA) are essential amino acids that are involved in various metabolic processes and are relevant in the context of Maple Syrup Urine Disease.)\n##\n(\"entity\"<|>MAPLE SYRUP URINE DISEASE<|>EVENT<|>Maple Syrup Urine Disease (MSUD) is a metabolic disorder characterized by a deficiency in the branched-chain alpha-keto acid dehydrogenase complex.)\n##\n(\"entity\"<|>PHENYLALANINE<|>EVENT<|>Phenylalanine (Phe) is an amino acid that is restricted in the diet of individuals with PKU to prevent toxic accumulation.)\n##\n(\"entity\"<|>BH4<|>ORGANIZATION<|>Tetrahydrobiopterin (BH4) is a cofactor that enhances tolerance to phenylalanine in PKU treatment.)\n##\n(\"entity\"<|>ENFERMEDAD DE ORINA DE JARABE DE ARCE<|>EVENT<|>Maple Syrup Urine Disease (EOJA) is an autosomal recessive disorder affecting the metabolism of branched-chain amino acids.)\n##\n(\"relationship\"<|>PKU<|>SA-PROPTERINA<|>Sapropterin is used as a treatment for managing phenylketonuria (PKU) by increasing tolerance to phenylalanine.<|>8)\n##\n(\"relationship\"<|>PKU<|>GLUCOMACROPEPTIDE<|>Glucomacropeptide is used in the dietary management of PKU to provide protein with low phenylalanine content.<|>8)\n##\n(\"relationship\"<|>PKU<|>BH4<|>Tetrahydrobiopterin (BH4) is a cofactor that improves the metabolic response in patients with PKU.<|>7)\n##\n(\"relationship\"<|>MAPLE SYRUP URINE DISEASE<|>BCAA<|>Maple Syrup Urine Disease is characterized by a metabolic defect involving branched-chain amino acids (BCAA).<|>9)\n##\n(\"relationship\"<|>PKU<|>PHENYLALANINE<|>Phenylalanine is the amino acid that must be restricted in the diet of individuals with PKU to prevent toxicity.<|>10)\n##\n(\"relationship\"<|>PKU<|>ENFERMEDAD DE ORINA DE JARABE DE ARCE<|>Both PKU and Maple Syrup Urine Disease are metabolic disorders that require dietary management of specific amino acids.<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Estos compiten con la Phe por los transportadores es-\n   d. Debe valorarse la suplementación con tirosina          pecíficos para atravesar la barrera hematoencefálica y\n       (100 mg/kg/día) durante el segundo-tercer tri-        la mucosa intestinal, utilizando mecanismo de inhibi-\n       mestre, así como valorar posible déficit de carniti-  ción competitiva. Si aumentamos el aporte de LNAA,\n       na, L-PUFA o micronutrientes5.                        disminuye el paso de Phe al cerebro.\n                                                                Esta opción terapéutica es más eficaz en aquellos pa-\n2.6.    Nuevas terapias                                      cientes con mala adherencia a la dieta10, 12.\n   Las limitaciones del tratamiento actual (dieta de por        Es necesario investigar sobre la composición óptima\nvida muy restringida, efectos secundarios de una dieta       de LNAA, efectos secundarios a largo plazo y beneficio\nde restricción proteica prolongada, posible afectación       a largo plazo en PKU.\nósea a pesar de la dieta y el desacoplamiento a la dieta        La dosis en adultos es de 18 g/día. Útil en adultos y\nque puede generar ciertos trastornos neurológicos e          ancianos con PKU8.\nincluso enfermedades neurodegenerativas en el adul-\nto) han hecho que en la actualidad se barajen otras          2.6.4.     Terapia génica\nposibilidades terapéuticas en el manejo de la PKU.              Son numerosas las investigaciones que, durante los\n                                                             últimos años, se vienen realizando acerca de la terapia\n2.6.1.     Coenzima tetrahidrobipterina                      génica en la PKU.\n   La BH4 es cofactor de PAH y se ha comprobado que             Dicha terapia está basada en la introducción de un gen\naumenta la tolerancia a la Phe, lo que permite liberali-     PAH funcional en células del paciente y en la expresión de\nzar la dieta, haciendo en algunos casos innecesaria la       la enzima hepática en tejido heterólogo como el músculo.\nfórmula especial.                                               Recientemente se ha demostrado una corrección\n   Existen estudios que permiten correlacionar la muta-      efectiva duradera en ratones, mediante la inyección in-\nción genética con la respuesta a BH46, 7. En la actuali-     tramuscular de un sistema completo de hidroxilación\ndad, la selección de pacientes con respuesta a BH4 se        de Phe, que incluye el gen PAH y dos genes esenciales\nrealiza mediante la realización de prueba de sobrecar-       para la síntesis de BH49.\nga de BH4 (20 mg/kg), considerándose como buena\nrespuesta si los valores de Phe en plasma disminuyen         3.   Enfermedad de orina de jarabe de arce\nigual o más del 30% del valor basal de Phe.                  3.1.    Consideraciones generales\n   Existen diferentes modalidades de prueba de sobre-\ncarga de BH4 (24 horas, 48 horas, 1 mes, etc.).                 La enfermedad de orina de jarabe de arce (EOJA;\n   En la actualidad existe un preparado comercial, Sa-       Maple syrup urine disease, MSUD) es una aminoacido-\npropterina (comprimidos 100 mg de administración             patía del metabolismo de los aa de cadena ramificada\nvía oral) y se han descrito pocos efectos secundarios        (leucina, valina e isoleucina; branched chain aminoa-\n(cefalea, rinorrea, molestias abdominales).                  cids, BCAA) como consecuencia de un déficit enzimáti-\n                                                             co del complejo deshidrogenasa (figura 2).\n2.6.2.     Glucomacropéptido (GMP)                              Es una enfermedad autosómica recesiva con una in-\n                                                             cidencia de 1/250000 recién nacidos vivos. Se distin-\n   Es un péptido grande obtenido en la industria láctea      guen cinco fenotipos clínicos y bioquímicos diferentes\na partir de la caseína que contiene cantidades muy pe-       (clásica, intermedia, intermitente, sensible a tiamina y\nqueñas de fenilalanina (2 mg/g). El preparado comer-         deficiencia del componente E3 del complejo multienzi-\ncial se obtiene a partir del queso, mejora el sabor y la     mático deshidrogenasa), pero de forma práctica en la\nvariedad de la dieta para PKU y está suplementado con        clínica podemos distinguir la forma neonatal (se ma-\narginina, histidina, leucina, tirosina y triptófano para\ncomplementar el aporte proteico11, 12 . Los productos        nifiesta como un cuadro tóxico en el neonato\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}